|
DOSAGE
|
Mild to moderate infection: 1 gtt q3hrs for 7-10 days (maximum of 6 doses per day)
|
|
GENERIC
|
trimethoprim 0.1% (1mg/mL), polymyxin B sulfate (10,000 units/mL)
|
|
INDICATIONS
|
POLYTRIM® Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis. Excellent coverage of Haemophilus influenzae and Streptococcus pneumoniae makes Polytrim popular in pediatric usage.
|
|
MECHANISM OF ACTION
|
Polypeptide / Sulfonamide: Trimethoprim - prevents bacterial folic acid synthesis (inhibits bacterial DNA synthesis). Polymyxin B - surfactant acts on phospholipids of bacterial cell membranes.
|
|
MICROBIOLOGY
|
POLYTRIM® are active against the following bacterial pathogens that are capable of causing external infections of the eye: Active against a wide variety of aerobic gram-positive and gram-negative Trimethoprim. Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus faecalis, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus aegyptius, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis (indole-negative), Proteus vulgaris (indole-positive), Enterobacter aerogenes and Serratia marcescens. Polymyxin B: Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes and Haemophilus influenzae.
|
|
CONTRAINDICATIONS & WARNINGS
|
POLYTRIM® Ophthalmic Solution is contraindicated in patients with known hypersensitivity to any of its components.
|
|
PEDIATRIC USE
|
Safety and effectiveness in children below the age of 2 months have not been established
|
|
PREGNANCY
|
Category C Teratogenic Effects Animal reproduction studies have not been conducted with polymyxin B sulfate. It is not known whether polymyxin B sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Because trimethoprim may interfere with folic acid metabolism, trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
|
|
NOTE
|
BAK, Useful as adjunctive therapy when fluoroquinolone resistance is suspected
|
